



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tasquinimod-d₃

Cat. No.:	HY-10528S		
CAS No.:	1416701-99-9		
Molecular Formula:	C ₂₀ H ₁₄ D ₃ F ₃ N ₂ O ₄		
Molecular Weight:	409.37		
Target:	HDAC; Isotope-Labeled Compounds		
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (244.28 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.4428 mL	12.2139 mL	24.4278 mL
5 mM	0.4886 mL	2.4428 mL	4.8856 mL
10 mM	0.2443 mL	1.2214 mL	2.4428 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Tasquinimod-d₃ (ABR-215050-d₃) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn²⁺ binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor^{[1][2][3]}.

REFERENCES

- [1]. Isaacs JT, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. *Cancer Res.* 2013 Feb 15;73(4):1386-99.
- [2]. Olsson A, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. *Mol Cancer.* 2010 May 17;9:107.
- [3]. Isaacs JT, et al. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. *Oncotarget.* 2014 Sep 30;5(18):8093-106.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA